• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

融合基因检测的测序策略。

Sequencing Strategies for Fusion Gene Detection.

机构信息

The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, NSW 2010, Australia.

Faculty of Medicine, St. Vincent's Clinical School, UNSW, St Vincent's Hospital, Victoria Street, Darlinghurst, NSW 2010, Australia.

出版信息

Bioessays. 2020 Jul;42(7):e2000016. doi: 10.1002/bies.202000016. Epub 2020 Apr 19.

DOI:10.1002/bies.202000016
PMID:32307742
Abstract

Fusion genes formed by chromosomal rearrangements are common drivers of cancer. Recent innovations in the field of next-generation sequencing (NGS) have seen a dynamic shift from traditional fusion detection approaches, such as visual characterization by fluorescence, to more precise multiplexed methods. There are many different NGS-based approaches to fusion gene detection and deciding on the most appropriate method can be difficult. Beyond the experimental approach, consideration needs to be given to factors such as the ease of implementation, processing time, associated costs, and the level of expertise required for data analysis. Here, the different NGS-based methods for fusion gene detection, the basic principles underlying the techniques, and the benefits and limitations of each approach are reviewed. This article concludes with a discussion of how NGS will impact fusion gene detection in a clinical context and from where the next innovations are evolving.

摘要

染色体重排形成的融合基因是癌症的常见驱动因素。近年来,下一代测序(NGS)领域的创新已经从传统的融合检测方法(如荧光可视化特征),发展到更精确的多重方法。有许多不同的基于 NGS 的融合基因检测方法,选择最合适的方法可能具有挑战性。除了实验方法外,还需要考虑诸如易于实施、处理时间、相关成本以及数据分析所需的专业水平等因素。在这里,我们回顾了用于融合基因检测的不同基于 NGS 的方法、技术的基本原理,以及每种方法的优缺点。本文最后讨论了 NGS 将如何在临床背景下影响融合基因检测,以及下一个创新点将从何处发展。

相似文献

1
Sequencing Strategies for Fusion Gene Detection.融合基因检测的测序策略。
Bioessays. 2020 Jul;42(7):e2000016. doi: 10.1002/bies.202000016. Epub 2020 Apr 19.
2
[Research progression of gene fusion detection technology based on next generation sequencing in tumor companion diagnostics].[基于新一代测序的基因融合检测技术在肿瘤伴随诊断中的研究进展]
Zhonghua Yu Fang Yi Xue Za Zhi. 2022 Dec 6;56(12):1880-1888. doi: 10.3760/cma.j.cn112150-20220615-00612.
3
Application of next generation sequencing to human gene fusion detection: computational tools, features and perspectives.下一代测序在人类基因融合检测中的应用:计算工具、特点和展望。
Brief Bioinform. 2013 Jul;14(4):506-19. doi: 10.1093/bib/bbs044. Epub 2012 Aug 9.
4
High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods.与当前常规方法相比,靶向二代测序在临床肿瘤标本变异检测中的高性能。
J Exp Clin Cancer Res. 2017 Sep 7;36(1):121. doi: 10.1186/s13046-017-0591-4.
5
Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing.通过连续DNA和RNA测序优化非小细胞肺癌中的突变和融合检测
J Thorac Oncol. 2020 Jun;15(6):1000-1014. doi: 10.1016/j.jtho.2020.01.019. Epub 2020 Jan 31.
6
A Multiplexed Amplicon Approach for Detecting Gene Fusions by Next-Generation Sequencing.一种用于通过下一代测序检测基因融合的多重扩增子方法。
J Mol Diagn. 2016 Mar;18(2):165-75. doi: 10.1016/j.jmoldx.2015.10.002. Epub 2015 Dec 30.
7
Intergenic Breakpoints Identified by DNA Sequencing Confound Targetable Kinase Fusion Detection in NSCLC.DNA 测序鉴定的基因间断点使 NSCLC 中可靶向的激酶融合检测复杂化。
J Thorac Oncol. 2020 Jul;15(7):1223-1231. doi: 10.1016/j.jtho.2020.02.023. Epub 2020 Mar 7.
8
Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers.下一代测序鉴定非小细胞肺癌中复杂 ALK 重排的分子特征和临床结局。
J Transl Med. 2021 Jul 16;19(1):308. doi: 10.1186/s12967-021-02982-4.
9
Overview of Fusion Detection Strategies Using Next-Generation Sequencing.使用下一代测序技术的融合检测策略概述
Methods Mol Biol. 2019;1908:125-138. doi: 10.1007/978-1-4939-9004-7_9.
10
Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing.使用锚定多重聚合酶链反应继以下一代测序进行致癌基因融合检测。
J Vis Exp. 2019 Jul 5(149). doi: 10.3791/59895.

引用本文的文献

1
Detection of cytogenetically cryptic PML-RARA fusion in acute promyelocytic leukemia by rapid next generation sequencing.通过快速下一代测序检测急性早幼粒细胞白血病中细胞遗传学隐匿性PML-RARA融合
NPJ Precis Oncol. 2025 Aug 9;9(1):279. doi: 10.1038/s41698-025-01072-8.
2
Identification of Molecular Subtypes of B-Cell Acute Lymphoblastic Leukemia in Mexican Children by Whole-Transcriptome Analysis.通过全转录组分析鉴定墨西哥儿童B细胞急性淋巴细胞白血病的分子亚型
Int J Mol Sci. 2025 Jul 21;26(14):7003. doi: 10.3390/ijms26147003.
3
The fusion characteristics of RET fusion in pan-cancer among the Chinese population: A comprehensive genomic analysis.
中国人群泛癌中RET融合的融合特征:一项全面的基因组分析。
Transl Oncol. 2025 May;55:102384. doi: 10.1016/j.tranon.2025.102384. Epub 2025 Apr 3.
4
Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC.基于 DNA 的全面基因组分析检测非鳞状 NSCLC 靶向融合的真实世界临床性能。
Oncologist. 2024 Aug 5;29(8):e984-e996. doi: 10.1093/oncolo/oyae028.
5
A unified DNA- and RNA-based NGS strategy for the analysis of multiple types of variants at the dual nucleic acid level in solid tumors.一种基于 DNA 和 RNA 的统一 NGS 策略,用于在实体瘤的双核酸水平上分析多种类型的变异。
J Clin Lab Anal. 2023 Oct;37(19-20):e24977. doi: 10.1002/jcla.24977. Epub 2023 Oct 25.
6
Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China.中国TRK融合癌患者的患病率及临床基因组特征
NPJ Precis Oncol. 2023 Aug 11;7(1):75. doi: 10.1038/s41698-023-00427-3.
7
Fusion sequencing via terminator-assisted synthesis (FTAS-seq) identifies TMPRSS2 fusion partners in prostate cancer.融合测序通过终结者辅助合成(FTAS-seq)鉴定前列腺癌中的 TMPRSS2 融合伙伴。
Mol Oncol. 2023 Jun;17(6):993-1006. doi: 10.1002/1878-0261.13428. Epub 2023 Apr 13.
8
ESR1 fusions and therapeutic resistance in metastatic breast cancer.雌激素受体1(ESR1)融合与转移性乳腺癌的治疗耐药性
Front Oncol. 2023 Jan 4;12:1037531. doi: 10.3389/fonc.2022.1037531. eCollection 2022.
9
Clinical Response to Seribantumab, an Anti-Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an Fusion.携带 融合的转移性胰腺导管腺癌患者对抗人表皮生长因子受体-3免疫球蛋白2单克隆抗体塞瑞昔单抗的临床反应
JCO Precis Oncol. 2022 Nov;6:e2200263. doi: 10.1200/PO.22.00263.
10
mRNA Capture Sequencing and RT-qPCR for the Detection of Pathognomonic, Novel, and Secondary Fusion Transcripts in FFPE Tissue: A Sarcoma Showcase.mRNA 捕获测序和 RT-qPCR 用于检测 FFPE 组织中的标志性、新型和次要融合转录本:肉瘤展示。
Int J Mol Sci. 2022 Sep 20;23(19):11007. doi: 10.3390/ijms231911007.